-
Mashup Score: 0Disadvantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Alberto Briganti - 1 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Alberto Briganti presents the disadvantages of using novel imaging in the management of non-metastatic castrate-resistant prostate cancer (nmCRPC) patients. Biographies: Alberto Briganti, MD, PhD, Associate Professor of Urology, San Raffaele, Milan, Italy Related Content: APCCC 2022: Disadvantages of Using Novel…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Advantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Michael Morris - 1 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Michael Morris presents on advantages of using novel imaging in nmCRPC. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer Section Head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Advantages of using novel imaging in #nmCRPC. #APCCC22 presentation by @morr316 @MSKCancerCenter. #WatchNow on UroToday > https://t.co/MRrDZvYFTf @APCCC_Lugano @Silke_Gillessen @AOmlin https://t.co/IH7ejrzP7k
-
-
Mashup Score: 0Advantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Michael Morris - 2 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Michael Morris presents on advantages of using novel imaging in nmCRPC. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer Section Head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Advantages of using novel imaging in #nmCRPC. #APCCC22 presentation by @morr316 @MSKCancerCenter. #WatchNow on UroToday > https://t.co/MRrDZvYFTf @APCCC_Lugano @Silke_Gillessen @AOmlin https://t.co/rvHBTRg6Ur
-
-
Mashup Score: 1Disadvantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Alberto Briganti - 2 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Alberto Briganti presents the disadvantages of using novel imaging in the management of non-metastatic castrate-resistant prostate cancer (nmCRPC) patients. Biographies: Alberto Briganti, MD, PhD, Associate Professor of Urology, San Raffaele, Milan, Italy Related Content: APCCC 2022: Disadvantages of Using Novel…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Disadvantages of using novel imaging in #nmCRPC. #APCCC22 presentation by @albertobrigant1 @SanRaffaeleMI. #WatchNow on UroToday > https://t.co/3YI6suQz7m @APCCC_Lugano @Silke_Gillessen @AOmlin @Ecastromarcos https://t.co/zxMYLWFDiO
-
-
Mashup Score: 0Neuropathy, Weight Loss Linked With Fall Risk in Apalutamide - 2 year(s) ago
Several factors may be associated with risk for falls among nmCRPC patients treated with apalutamide and ongoing androgen deprivation therapy.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with #nmCRPC who are treated with apalutamide and ongoing androgen deprivation therapy have been found to be at increased risk of falls due to post-treatment #neuropathy, weight loss, and arthralgia. Learn more: https://t.co/7IEnJxt1qj https://t.co/grLzYfAIi1
-
-
Mashup Score: 2Advantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Michael Morris - 2 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Michael Morris presents on advantages of using novel imaging in nmCRPC. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer Section Head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Advantages of using novel imaging in #nmCRPC. #APCCC22 presentation by @morr316 @MSKCancerCenter. #WatchNow on UroToday > https://t.co/MRrDZvYFTf @APCCC_Lugano @Silke_Gillessen @AOmlin https://t.co/yIV3hr5KP9
-
-
Mashup Score: 0Disadvantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Alberto Briganti - 2 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Alberto Briganti presents the disadvantages of using novel imaging in the management of non-metastatic castrate-resistant prostate cancer (nmCRPC) patients. Biographies: Alberto Briganti, MD, PhD, Associate Professor of Urology, San Raffaele, Milan, Italy Related Content: APCCC 2022: Disadvantages of Using Novel…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Disadvantages of using novel imaging in #nmCRPC. #APCCC22 presentation by @albertobrigant1 @SanRaffaeleMI. #WatchNow on UroToday > https://t.co/3YI6sv8avW @APCCC_Lugano @Silke_Gillessen @AOmlin @Ecastromarcos https://t.co/aIds68j6Fd
-
-
Mashup Score: 0ESMO 2022: Real-World First-Line Treatment Patterns in Patients with High-Risk nmCRPC - 2 year(s) ago
ESMO 2022 first-line treatment patterns in patients with high-risk nmCRPC, apalutamide, darolutamide, or enzalutamide, high-risk nmCRPC in the United States, real-world use of novel hormone therapies in men with high-risk nmCRPC.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Real-world first-line treatment patterns in patients with high-risk #nmCRPC. Presentation by Sumati Gupta, MD @huntsmancancer. #ESMO22 written coverage by @zklaassen_md @GACancerCenter > https://t.co/cdVsmrBQnM @myESMO @UofUHealth https://t.co/uaZOi5CgfD
-
-
Mashup Score: 0Advantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Michael Morris - 2 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Michael Morris presents on advantages of using novel imaging in nmCRPC. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer Section Head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Advantages of using novel imaging in #nmCRPC. #APCCC22 presentation by @morr316 @MSKCancerCenter. #WatchNow on UroToday > https://t.co/MRrDZvYFTf @APCCC_Lugano @Silke_Gillessen @AOmlin https://t.co/PYAD7Ho7MK
-
-
Mashup Score: 1Disadvantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Alberto Briganti - 2 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Alberto Briganti presents the disadvantages of using novel imaging in the management of non-metastatic castrate-resistant prostate cancer (nmCRPC) patients. Biographies: Alberto Briganti, MD, PhD, Associate Professor of Urology, San Raffaele, Milan, Italy Related Content: APCCC 2022: Disadvantages of Using Novel…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Disadvantages of using novel imaging in #nmCRPC. #APCCC22 presentation by @albertobrigant1 @SanRaffaeleMI. #WatchNow on UroToday > https://t.co/3YI6sv8avW @APCCC_Lugano @Silke_Gillessen @AOmlin @Ecastromarcos https://t.co/OjY5YZAwjf
-
Disadvantages of using novel imaging in #nmCRPC. #APCCC22 presentation by @albertobrigant1 @SanRaffaeleMI. #WatchNow on UroToday > https://t.co/3YI6sv8avW @APCCC_Lugano @Silke_Gillessen @AOmlin @Ecastromarcos https://t.co/2jDv0wUxJy